Table 2.
CyA, SU5402 dose, and PD/PI formation
| Assay/probe | Treatment
|
|||||||
|---|---|---|---|---|---|---|---|---|
| DMSO | 0.9 μm SU | 1.8 μm SU | 3 μm SU | 20 μm CyA | 20 μm CyA +0.9 μm SU | 20 μm CyA +1.8 μm SU | 20 μm CyA +3 μm SU | |
| nkx2.2a/pomc anterior (PD) | ||||||||
| wt | 100% | 100% | 100% | |||||
| Reduced | 100% | |||||||
| Absent | 100% | 100% | 100% | 100% | ||||
| Embryos, n | 16 | 15 | 16 | 18 | 16 | 15 | 16 | 16 |
| prl (PD) | ||||||||
| wt | 100% | 100% | 100% | 12% | 25% | 11% | ||
| Reduced | 88% | 75% | 78% | 100% | 54% | |||
| Absent | 11% | 46% | ||||||
| Embryos, n | 30 | 15 | 17 | 33 | 20 | 18 | 17 | 13 |
| pax7 (PI) | ||||||||
| Expanded | 50% | 22% | ||||||
| wt | 100% | 62% | 50% | |||||
| Reduced | 38% | 24% | 78% | 47% | 31% | |||
| Absent | 76% | 100% | 53% | 69% | ||||
| Embryos, n | 30 | 16 | 17 | 33 | 20 | 18 | 17 | 13 |
| lim3 (AH) | ||||||||
| wt | 100% | 47% | 22% | 27% | ||||
| Reduced | 53% | 78% | 67% | 73% | 100% | 100% | 27% | |
| Absent | 33% | 73% | ||||||
| Embryos, n | 17 | 19 | 18 | 15 | 15 | 16 | 16 | 22 |
AH, Entire adenohypophysis; SU, SU5402; wt, wild type.